优势价格
快速发货
品质保证
技术支持
400-920-2911 sales@csnpharm.cn
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN28491 | XY028-133 | 2229974-73-4 | XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity. |
| CSN22287 | THAL-SNS-032 | 2139287-33-3 | THAL-SNS-032 is a selective PROTAC, consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN), targeting on CDK9. |
| CSN28485 | PROTAC CDK9 degrader-2 | 2435721-30-3 | PROTAC CDK9 degrader-2 (compounds 11c) is a potent and selective CDK9 degrader based on PROTAC, with an IC50 of 17 μM in MCF-7 cell lines. Natural product Wogonin binds ubiquitin E3 ligase cereblon (CRBN) via a linker to form PROTAC. |
| CSN22310 | PROTAC CDK9 Degrader-1 | 2118356-96-8 | PROTAC CDK9 Degrader-1 is a CRBN-recruiting PROTAC selectively targeting on CDK9, consist of a CDK9 ligand (aminopyrazole analog) linked to a CRBN E3 ligand thalidomide. |
| CSN22284 | JH-XI-10-02 | 2209085-22-1 | JH-XI-10-02 is a PROTAC selectively targeting on CDK8 with IC50 value of 159nM, and is consist of a warhead target on CDK8 (a Cortistatin A derivate) linked to CRBN ligand Pomalidomide. |
| CSN28453 | CP-10 | 2366268-80-4 | CP-10 is a PROTAC targeting on CDK4/6 with DC50 values of 150-180 nM and 2.1 nM, respectively. It was generated by linking CDK6 inhibitor palbociclib and E3 ligase CRBN recruiter pomalidomide. |
| CSN28466 | BSJ-04-132 | 2349356-39-2 | BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC50s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity. |
| CSN28469 | BSJ-03-204 | 2349356-09-6 | BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity. |
| CSN23969 | BSJ-03-123 | 2361493-16-3 | BSJ-03-123 is a PROTAC selectively targeting on CDK6, consist of a warhead palbociclib (a CDK inhibitor) linked to a CRBN ligand pomalidomide. |
